Investing carries serious risks, including partial or total loss of capital. Please read the Key Investment Information Sheet and the Risk factors and login before investing.
CuraVac 1A
Targeted active therapies for a world without autoimmune diseases
Key Investment Information Sheet
Terms & Conditions
De-Risked Growth: Niche veterinary market of a severe disease, Positioned for High-Value Returns
CuraVac has advanced its lead asset, a Targeted Active Therapy for Myasthenia Gravis (CV-MG01), through early clinical milestones by leveraging approximately €18 million in total grants, non-dilutive funding, and early-stage investments across its human and canine R&D programmes, while operating with a lean cost structure.
CuraVac benefits from a grant / recoverable loan of €3.6 million from the Walloon Region that matches one-to-one any R&D investment in the clinical development of its Targeted Active Therapy for Myasthenia Gravis, in essence doubling each euro invested (up to that amount).
CuraVac is now dedicating resources to its canine immunotherapy programme as the first commercial step of its broader TAT platform strategy. This canine-first approach is supported by solid scientific evidence, favourable new EU regulations for rare veterinary conditions that accept the efficacy data presented for rare veterinary conditions, and a realistic prospect of meaningful revenue within two years.
These canine developments simultaneously support and accelerate the validation of the Targeted Active Therapy for the human Myasthenia Gravis market.
Veterinary Market Opportunity & Upside
- Annual market potential for CV-MG01: €11.1M (Europe + US), which should triple in size and value from the pool of undiagnosed cases, broader indications and adoption, and expansion into other market territories.
- Positioned for strategic partnerships with veterinary pharmaceutical companies.
CuraVac’s canine MG programme represents a perfect springboard for CuraVac and its investors.
From € millions in veterinary healthcare…
…to € billions in human healthcare
The human MG market, a multi-billion-euro opportunity: The global market for Myasthenia Gravis therapies is forecast by industry analysts to reach $6.7 billion by 2032 (in the 5 main EU markets, USA, and Japan). Three recently launched maintenance therapies already each generate more than $1 billion in annual revenue, yet none offers a durable remission. They require lifelong administration at $250,000 to $650,000 per patient per year.
We expect that, once reaching market authorisation, a product delivering long-lasting improvement with only 3 injections will rapidly become the preferred first line treatment and quickly surpass the combined revenue of all current market products.
Scorecard
The Scorecard is a tool designed to help investors make more informed decisions when considering investments in start-up companies. It provides an overview of a company's current situation. Developed by Spreds, it offers an objective score based on a defined set of key factors, often identified by academic research as indicators of a start-up's potential for success. The documents provided by the project owner were received by Spreds and made available to (potential) investors. The content of these documents was not analyzed by Spreds nor Spreds Finance.
Raise summary
| Crowd investments | €0 |
| Committed by others | €650,000 |
| Amount raised | €650,000 |
| Minimum round | €200,000 |
| Maximum round | €1,625,000 |
| Shares in the company (total round) | 6.341% |
| Pre-money valuation | €24,000,000 |
| Post-money valuation min. | €24,200,000 |
| Post-money valuation max. | €25,625,000 |